Moderna wins FDA approval for updated 2026-2027 COVID-19 vaccines targeting JN.1-lineage XFG subvariant
MRNA•FDA clears updated COVID-19 vaccine formulas
Moderna wins FDA approval for updated 2026-2027 COVID-19 vaccine formulas targeting the JN.1-lineage XFG subvariant via sBLA approvals.
- Spikevax label covers high-risk patients aged 6 months to 64 years, plus all adults 65 years and older.
- mNEXSPIKE label covers high-risk patients aged 12 to 64 years, plus all adults 65 years and older.
- Rollout is expected in the coming days, aligning product supply with the FDA’s monovalent JN.1-lineage XFG composition guidance.
